Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $456 from $476 and keeps an Equal Weight rating on the shares. Following the recent Phase 2 2 lumbosacral radiculopathy chronic pain data, the firm lowered its view on the odds of Suzetrigine success and sales in this setting, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Zai Lab, Vertex Pharmaceuticals announce povetacicept license agreement
- Vertex Pharmaceuticals, Orna Therapeutics announce research collaboration
- Yum, Ralph Lauren upgraded: Wall Street’s top analyst calls
- Top 3 Trending Stocks, According to Analysts – 12/25/2024
- Vertex Pharmaceuticals price target lowered to $460 from $550 at Truist